메뉴 건너뛰기




Volumn 4, Issue 10, 2013, Pages 1307-1320

Cancer immunotherapy: Accomplishments to date and future promise

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84885594301     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.88     Document Type: Review
Times cited : (115)

References (117)
  • 1
    • 84865552100 scopus 로고    scopus 로고
    • Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer
    • Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23, viii6-viii9 (2012).
    • (2012) Ann. Oncol , vol.23 , pp. 86-89
    • Finn, O.J.1
  • 2
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.2
  • 3
    • 79953151458 scopus 로고    scopus 로고
    • Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion
    • Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
    • (2011) Science , vol.331 , pp. 1565-1570
    • Schreiber, R.D.1    Old, L.J.2    Smyth, M.J.3
  • 4
    • 84965092294 scopus 로고
    • Cancer: A biological approach. I. The processes of control
    • Burnet M. Cancer: a biological approach. I. The processes of control. Br. Med. J. 1, 779-786 (1957).
    • (1957) Br. Med. J , vol.1 , pp. 779-786
    • Burnet, M.1
  • 5
    • 34547657483 scopus 로고    scopus 로고
    • Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience
    • Roithmaier S, Haydon AM, Loi S et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J. Heart Lung Transpl. 26, 845-849 (2007).
    • (2007) J. Heart Lung Transpl , vol.26 , pp. 845-849
    • Roithmaier, S.1    Haydon, A.M.2    Loi, S.3
  • 6
    • 70349256093 scopus 로고    scopus 로고
    • Cancer incidence and risk factors after solid organ transplantation
    • Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int. J. Cancer 125, 1747-1754 (2009).
    • (2009) Int. J. Cancer , vol.125 , pp. 1747-1754
    • Vajdic, C.M.1    Van Leeuwen, M.T.2
  • 7
    • 0027478361 scopus 로고
    • Identification of human cancers deficient in antigen processing
    • Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265-272 (1993).
    • (1993) J. Exp. Med , vol.177 , pp. 265-272
    • Restifo, N.P.1    Esquivel, F.2    Kawakami, Y.3
  • 9
    • 0022616253 scopus 로고
    • Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
    • Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675-678 (1986).
    • (1986) Nature , vol.319 , pp. 675-678
    • Karre, K.1    Ljunggren, H.G.2    Piontek, G.3    Kiessling, R.4
  • 10
    • 70449193189 scopus 로고
    • Immunity to methylcholanthrene-induced sarcomas
    • Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769-778 (1957).
    • (1957) J. Natl Cancer Inst , vol.18 , pp. 769-778
    • Prehn, R.T.1    Main, J.M.2
  • 11
    • 0026322151 scopus 로고
    • A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
    • van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991).
    • (1991) Science , vol.254 , pp. 1643-1647
    • Van Der Bruggen, P.1    Traversari, C.2    Chomez, P.3
  • 12
    • 27244448135 scopus 로고    scopus 로고
    • Tumor antigens and tumor antigen discovery
    • Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treat. Res. 123, 89-111 (2005).
    • (2005) Cancer Treat. Res , vol.123 , pp. 89-111
    • Graziano, D.F.1    Finn, O.J.2
  • 14
    • 0242266480 scopus 로고    scopus 로고
    • Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression
    • Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br. J. Cancer 89, 1345-1351 (2003).
    • (2003) Br. J. Cancer , vol.89 , pp. 1345-1351
    • Houston, A.1    Bennett, M.W.2    O'Sullivan, G.C.3    Shanahan, F.4    O'Connell, J.5
  • 15
    • 35948933046 scopus 로고    scopus 로고
    • Transforming growth factor-b and the immune response to malignant disease
    • Teicher BA. Transforming growth factor-b and the immune response to malignant disease. Clin. Cancer Res. 13, 6247-6251 (2007).
    • (2007) Clin. Cancer Res , vol.13 , pp. 6247-6251
    • Teicher, B.A.1
  • 16
    • 0142137237 scopus 로고    scopus 로고
    • Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
    • Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274 (2003).
    • (2003) Nat. Med , vol.9 , pp. 1269-1274
    • Uyttenhove, C.1    Pilotte, L.2    Theate, I.3
  • 17
    • 33847388907 scopus 로고    scopus 로고
    • Indoleamine 2,3-dioxygenase in immune suppression and cancer
    • Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr. Cancer Drug Targets 7, 31-40 (2007).
    • (2007) Curr. Cancer Drug Targets , vol.7 , pp. 31-40
    • Muller, A.J.1    Prendergast, G.C.2
  • 18
    • 0032555614 scopus 로고    scopus 로고
    • Prevention of allogeneic fetal rejection by tryptophan catabolism
    • Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998).
    • (1998) Science , vol.281 , pp. 1191-1193
    • Munn, D.H.1    Zhou, M.2    Attwood, J.T.3
  • 19
    • 33645286546 scopus 로고    scopus 로고
    • Regulatory T cells, tumour immunity and immunotherapy
    • Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307 (2006).
    • (2006) Nat. Rev. Immunol , vol.6 , pp. 295-307
    • Zou, W.1
  • 20
    • 0035874949 scopus 로고    scopus 로고
    • Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
    • Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766-4772 (2001).
    • (2001) Cancer Res , vol.61 , pp. 4766-4772
    • Woo, E.Y.1    Chu, C.S.2    Goletz, T.J.3
  • 21
    • 34548804503 scopus 로고    scopus 로고
    • Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma
    • Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 67, 8865-8873 (2007).
    • (2007) Cancer Res , vol.67 , pp. 8865-8873
    • Bergmann, C.1    Strauss, L.2    Zeidler, R.3    Lang, S.4    Whiteside, T.L.5
  • 22
    • 34347375745 scopus 로고    scopus 로고
    • Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment
    • Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside T. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol. Immunother. 56, 1429-1442 (2007).
    • (2007) Cancer Immunol. Immunother , vol.56 , pp. 1429-1442
    • Bergmann, C.1    Strauss, L.2    Zeidler, R.3    Lang, S.4    Whiteside, T.5
  • 23
    • 33645502885 scopus 로고    scopus 로고
    • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
    • Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, 3294-3302 (2006).
    • (2006) Cancer Res , vol.66 , pp. 3294-3302
    • Fecci, P.E.1    Mitchell, D.A.2    Whitesides, J.F.3
  • 25
    • 0030240952 scopus 로고    scopus 로고
    • Immunotherapy for cancer
    • Old LJ. Immunotherapy for cancer. Sci. Am. 275, 136-143 (1996).
    • (1996) Sci. Am , vol.275 , pp. 136-143
    • Old, L.J.1
  • 26
    • 0026060863 scopus 로고
    • The treatment of malignant tumors by repeated inoculations of erysipelas. with a report of ten original cases. 1893
    • Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. 262, 3-11 (1991).
    • (1991) Clin. Orthop. Relat. Res , vol.262 , pp. 3-11
    • Coley, W.B.1
  • 27
    • 84865547199 scopus 로고    scopus 로고
    • Can immuno-oncology offer a truly pan-Tumour approach to therapy?
    • Eggermont AMM. Can immuno-oncology offer a truly pan-Tumour approach to therapy? Annals Oncol. 23, viii53-viii57 (2012).
    • (2012) Annals Oncol , vol.23 , pp. 853-857
    • Amm, E.1
  • 28
    • 0025148037 scopus 로고
    • The spontaneous regression of cancer. A review of cases from 1900 to 1987
    • Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 29, 545-550 (1990).
    • (1990) Acta Oncol , vol.29 , pp. 545-550
    • Challis, G.B.1    Stam, H.J.2
  • 29
    • 45549092607 scopus 로고    scopus 로고
    • Cancer immunology
    • Finn OJ. Cancer immunology. N. Engl. J. Med. 358, 2704-2715 (2008).
    • (2008) N. Engl. J. Med , vol.358 , pp. 2704-2715
    • Finn, O.J.1
  • 30
    • 0028266553 scopus 로고
    • Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
    • Rosenberg AA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913 (1994).
    • (1994) JAMA , vol.271 , pp. 907-913
    • Rosenberg, A.A.1    Yang, J.C.2    Topalian, S.L.3
  • 31
    • 0035863468 scopus 로고    scopus 로고
    • Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    • Olsen E, Duvic M, Frankel A et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376-388 (2001).
    • (2001) J. Clin. Oncol , vol.19 , pp. 376-388
    • Olsen, E.1    Duvic, M.2    Frankel, A.3
  • 33
    • 34247504608 scopus 로고    scopus 로고
    • Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro
    • Mahnke K, Schönfeld K, Fondel S et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120, 2723-2733 (2007).
    • (2007) Int. J. Cancer , vol.120 , pp. 2723-2733
    • Mahnke, K.1    Schönfeld, K.2    Fondel, S.3
  • 34
    • 0037350545 scopus 로고    scopus 로고
    • Immunotherapy: Past, present and future
    • Waldmann TA. Immunotherapy: past, present and future. Nat. Med. 9, 269-277 (2003).
    • (2003) Nat. Med , vol.9 , pp. 269-277
    • Waldmann, T.A.1
  • 35
    • 84858416256 scopus 로고    scopus 로고
    • Antibody-based immunotherapy of cancer
    • Weiner L, Murray J, Shuptrine C. Antibody-based immunotherapy of cancer. Cell 148, 1081-1084 (2012).
    • (2012) Cell , vol.148 , pp. 1081-1084
    • Weiner, L.1    Murray, J.2    Shuptrine, C.3
  • 36
    • 80054092984 scopus 로고    scopus 로고
    • Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends
    • Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin. Cancer Res. 17, 6406-6416 (2011).
    • (2011) Clin. Cancer Res , vol.17 , pp. 6406-6416
    • Steiner, M.1    Neri, D.2
  • 37
    • 0034614897 scopus 로고    scopus 로고
    • Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
    • Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423-434 (2000).
    • (2000) J. Exp. Med , vol.191 , pp. 423-434
    • Sauter, B.1    Albert, M.L.2    Francisco, L.3    Larsson, M.4    Somersan, S.5    Bhardwaj, N.6
  • 38
    • 0037033448 scopus 로고    scopus 로고
    • Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells
    • Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195, 125-133 (2002).
    • (2002) J. Exp. Med , vol.195 , pp. 125-133
    • Dhodapkar, K.M.1    Krasovsky, J.2    Williamson, B.3    Dhodapkar, M.V.4
  • 39
    • 65549085367 scopus 로고    scopus 로고
    • Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: Support for a "vaccinal effect" Of rituximab
    • Hilchey SP, Hyrien O, Mosmann TR et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 113, 3809-3812 (2009).
    • (2009) Blood , vol.113 , pp. 3809-3812
    • Hilchey, S.P.1    Hyrien, O.2    Mosmann, T.R.3
  • 41
    • 33749319703 scopus 로고    scopus 로고
    • Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    • Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
    • (2006) Science , vol.313 , pp. 1960-1964
    • Galon, J.1    Costes, A.2    Sanchez-Cabo, F.3
  • 42
    • 29144514645 scopus 로고    scopus 로고
    • Effector memory T cells, early metastasis, and survival in colorectal cancer
    • Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2005).
    • (2005) N. Engl. J. Med , vol.353 , pp. 2654-2666
    • Pages, F.1    Berger, A.2    Camus, M.3
  • 43
    • 79952093380 scopus 로고    scopus 로고
    • Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction
    • Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29, 610-618 (2011).
    • (2011) J. Clin. Oncol , vol.29 , pp. 610-618
    • Mlecnik, B.1    Tosolini, M.2    Kirilovsky, A.3
  • 44
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
    • (2010) N. Engl. J. Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 45
    • 79957831345 scopus 로고    scopus 로고
    • Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
    • Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119-2127 (2011).
    • (2011) N. Engl. J. Med , vol.364 , pp. 2119-2127
    • Schwartzentruber, D.J.1    Lawson, D.H.2    Richards, J.M.3
  • 46
    • 84880745167 scopus 로고    scopus 로고
    • Prediction of response to anticancer immunotherapy using gene signatures
    • Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J. Clin. Oncol. 31, 2369-2371 (2013).
    • (2013) J. Clin. Oncol , vol.31 , pp. 2369-2371
    • Wang, E.1    Bedognetti, D.2    Marincola, F.M.3
  • 47
    • 84880730418 scopus 로고    scopus 로고
    • Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized Phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
    • Kruit WHJ, Suciu S, Dreno B et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized Phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J. Clin. Oncol. 31, 2413-2420 (2013).
    • (2013) J. Clin. Oncol , vol.31 , pp. 2413-2420
    • Whj, K.1    Suciu, S.2    Dreno, B.3
  • 48
    • 84880755387 scopus 로고    scopus 로고
    • Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results
    • Vansteenkiste J, Zielinski M, Linder A et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J. Clin. Oncol. 31, 2396-2403 (2013).
    • (2013) J. Clin. Oncol , vol.31 , pp. 2396-2403
    • Vansteenkiste, J.1    Zielinski, M.2    Linder, A.3
  • 49
    • 84880720167 scopus 로고    scopus 로고
    • Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy
    • Ulloa-Montoya F, Louahed J, Dizier B et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31, 2388-2395 (2013).
    • (2013) J. Clin. Oncol , vol.31 , pp. 2388-2395
    • Ulloa-Montoya, F.1    Louahed, J.2    Dizier, B.3
  • 50
    • 77954899030 scopus 로고    scopus 로고
    • Phase i study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
    • Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
    • (2010) J. Clin. Oncol , vol.28 , pp. 3167-3175
    • Brahmer, J.R.1    Drake, C.G.2    Wollner, I.3
  • 51
    • 79953154967 scopus 로고    scopus 로고
    • CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
    • Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
    • (2011) Science , vol.331 , pp. 1612-1616
    • Beatty, G.L.1    Chiorean, E.G.2    Fishman, M.P.3
  • 52
    • 49149088707 scopus 로고    scopus 로고
    • Next generation of immunotherapy for melanoma
    • Kirkwood JM, Tarhini AA, Panelli MC et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26, 3445-3455 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 3445-3455
    • Kirkwood, J.M.1    Tarhini, A.A.2    Panelli, M.C.3
  • 53
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
    • (2013) N. Engl. J. Med , vol.369 , pp. 122-133
    • Wolchok, J.D.1    Kluger, H.2    Callahan, M.K.3
  • 54
    • 84885659813 scopus 로고    scopus 로고
    • Prostate cancer vaccines: Update on clinical development
    • Geary SM, Salem AK. Prostate cancer vaccines: update on clinical development. Oncoimmunology 2(5) e24523 (2013).
    • (2013) Oncoimmunology , vol.2 , Issue.5
    • Geary, S.M.1    Salem, A.K.2
  • 55
    • 84865408266 scopus 로고    scopus 로고
    • Prostate cancer vaccines in clinical trials
    • Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev. Vaccines 11, 857-868 (2012).
    • (2012) Expert Rev. Vaccines , vol.11 , pp. 857-868
    • Lubaroff, D.M.1
  • 56
    • 84861988397 scopus 로고    scopus 로고
    • Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
    • Sims RB. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 30, 4394-4397 (2012).
    • (2012) Vaccine , vol.30 , pp. 4394-4397
    • Sims, R.B.1
  • 57
    • 0035522738 scopus 로고    scopus 로고
    • Dendritic cell-based treatment of cancer: Closing in on a cellular therapy
    • Valone FH, Small E, MacKenzie M, et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 7(Suppl. 2), S53-S61 (2001).
    • (2001) Cancer J , vol.7 SUPPL. 2
    • Valone, F.H.1    Small, E.2    Mackenzie, M.3
  • 58
    • 84862769116 scopus 로고    scopus 로고
    • An immune-Active tumor microenvironment favors clinical response to ipilimumab
    • Ji RR, Chasalow S, Wang L et al. An immune-Active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019-1031 (2012).
    • (2012) Cancer Immunol. Immunother , vol.61 , pp. 1019-1031
    • Ji, R.R.1    Chasalow, S.2    Wang, L.3
  • 59
    • 82155168544 scopus 로고    scopus 로고
    • A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
    • Hamid O, Schmidt H, Nissan A et al. A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9, 204 (2011).
    • (2011) J. Transl. Med , vol.9 , Issue.204
    • Hamid, O.1    Schmidt, H.2    Nissan, A.3
  • 60
    • 84655167968 scopus 로고    scopus 로고
    • Programmed cell removal: A new obstacle in the road to developing cancer
    • Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nat. Rev. Cancer 12, 58-67 (2012).
    • (2012) Nat. Rev. Cancer , vol.12 , pp. 58-67
    • Chao, M.P.1    Majeti, R.2    Weissman, I.L.3
  • 61
    • 67650632683 scopus 로고    scopus 로고
    • CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells
    • Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
    • (2009) Cell , vol.138 , pp. 286-299
    • Majeti, R.1    Chao, M.P.2    Alizadeh, A.A.3
  • 62
    • 77954676136 scopus 로고    scopus 로고
    • The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized Phase II/III trial
    • Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized Phase II/III trial. Int. J. Cancer 127, 2209- 2221 (2010).
    • (2010) Int. J. Cancer , vol.127 , pp. 2209-2221
    • Heiss, M.M.1    Murawa, P.2    Koralewski, P.3
  • 63
    • 58149384550 scopus 로고    scopus 로고
    • Graft-versus-leukemia effects of transplantation and donor lymphocytes
    • Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371-4383 (2008).
    • (2008) Blood , vol.112 , pp. 4371-4383
    • Kolb, H.J.1
  • 64
    • 0018764352 scopus 로고
    • Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
    • Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
    • (1979) N. Engl. J. Med , vol.300 , pp. 1068-1073
    • Weiden, P.L.1    Flournoy, N.2    Thomas, E.D.3
  • 65
    • 79960299888 scopus 로고    scopus 로고
    • Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
    • Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557 (2011).
    • (2011) Clin. Cancer Res , vol.17 , pp. 4550-4557
    • Rosenberg, S.A.1    Yang, J.C.2    Sherry, R.M.3
  • 66
    • 79953033883 scopus 로고    scopus 로고
    • Establishment and large-scale expansion of minimally cultured 'young' tumor infiltrating lymphocytes for adoptive transfer therapy
    • Itzhaki O, Hovav E, Ziporen Y et al. Establishment and large-scale expansion of minimally cultured 'young' tumor infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 34, 212-220 (2011).
    • (2011) J. Immunother , vol.34 , pp. 212-220
    • Itzhaki, O.1    Hovav, E.2    Ziporen, Y.3
  • 67
    • 77951714425 scopus 로고    scopus 로고
    • Clinical responses in a Phase II study using adoptive transfer of short-Term cultured tumor infiltration lymphocytes in metastatic melanoma patients
    • Besser MJ, Shapira-Frommer R, Treves AJ et al. Clinical responses in a Phase II study using adoptive transfer of short-Term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646-2655 (2010).
    • (2010) Clin. Cancer Res , vol.16 , pp. 2646-2655
    • Besser, M.J.1    Shapira-Frommer, R.2    Treves, A.J.3
  • 68
    • 84886944380 scopus 로고    scopus 로고
    • Trial watch. Adoptive cell transfer immunotherapy
    • Galluzzi L, Vacchelli E, Eggermont A et al. Trial watch. Adoptive cell transfer immunotherapy. Oncoimmunology 1, 306-315 (2012).
    • (2012) Oncoimmunology , vol.1 , pp. 306-315
    • Galluzzi, L.1    Vacchelli, E.2    Eggermont, A.3
  • 69
    • 0037365973 scopus 로고    scopus 로고
    • Phase II trial of autologous tumor vaccination, anti-CD3-Activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer
    • Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, anti-CD3-Activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol. 21, 884-890 (2003).
    • (2003) J. Clin. Oncol , vol.21 , pp. 884-890
    • Chang, A.E.1    Li, Q.2    Jiang, G.3    Sayre, D.M.4    Braun, T.M.5    Redman, B.G.6
  • 70
    • 0141456489 scopus 로고    scopus 로고
    • A Phase i trial of CD3/CD28-Activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma
    • Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW. A Phase I trial of CD3/CD28-Activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 9, 3562-3570 (2003).
    • (2003) Clin. Cancer Res , vol.9 , pp. 3562-3570
    • Thompson, J.A.1    Figlin, R.A.2    Sifri-Steele, C.3    Berenson, R.J.4    Frohlich, M.W.5
  • 71
    • 78751689288 scopus 로고    scopus 로고
    • Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
    • Hinrichs CS, Borman ZA, Gattinoni L et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808-814 (2011).
    • (2011) Blood , vol.117 , pp. 808-814
    • Hinrichs, C.S.1    Borman, Z.A.2    Gattinoni, L.3
  • 72
    • 0035575701 scopus 로고    scopus 로고
    • Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity
    • Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356-6365 (2001).
    • (2001) J. Immunol , vol.167 , pp. 6356-6365
    • Liu, K.1    Rosenberg, S.A.2
  • 73
    • 20144387943 scopus 로고    scopus 로고
    • Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: Eradication of autologous mouse prostate cancer
    • Zhang Q, Yang X, Pins M et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65, 1761-1769 (2005).
    • (2005) Cancer Res , vol.65 , pp. 1761-1769
    • Zhang, Q.1    Yang, X.2    Pins, M.3
  • 74
    • 27744450650 scopus 로고    scopus 로고
    • Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy
    • Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052 (2005).
    • (2005) J. Immunol , vol.175 , pp. 7046-7052
    • Zhou, J.1    Shen, X.2    Huang, J.3    Hodes, R.J.4    Rosenberg, S.A.5    Robbins, P.F.6
  • 75
    • 77955177074 scopus 로고    scopus 로고
    • Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein
    • Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J. Immunother. 33, 672-683 (2010).
    • (2010) J. Immunother , vol.33 , pp. 672-683
    • Kalbasi, A.1    Shrimali, R.K.2    Chinnasamy, D.3    Rosenberg, S.A.4
  • 76
    • 80455162464 scopus 로고    scopus 로고
    • Inducible apoptosis as a safety switch for adoptive cell therapy
    • Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
    • (2011) N. Engl. J. Med , vol.365 , pp. 1673-1683
    • Di Stasi, A.1    Tey, S.K.2    Dotti, G.3
  • 77
    • 70149114880 scopus 로고    scopus 로고
    • Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    • Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
    • (2009) Blood , vol.114 , pp. 535-546
    • Johnson, L.A.1    Morgan, R.A.2    Dudley, M.E.3
  • 78
    • 0033168142 scopus 로고    scopus 로고
    • Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-Tumor reactivity
    • Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-Tumor reactivity. J. Immunol. 163, 507-513 (1999).
    • (1999) J. Immunol , vol.163 , pp. 507-513
    • Clay, T.M.1    Custer, M.C.2    Sachs, J.3    Hwu, P.4    Rosenberg, S.A.5    Nishimura, M.I.6
  • 79
    • 33749624177 scopus 로고    scopus 로고
    • Cancer regression in patients after transfer of genetically engineered lymphocytes
    • Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
    • (2006) Science , vol.314 , pp. 126-129
    • Morgan, R.A.1    Dudley, M.E.2    Wunderlich, J.R.3
  • 80
    • 84872577768 scopus 로고    scopus 로고
    • Genetically engineered T cells for the treatment of cancer
    • Essand M, Loskog ASI. Genetically engineered T cells for the treatment of cancer. J. Intern. Med. 273, 166-181 (2013).
    • (2013) J. Intern. Med , vol.273 , pp. 166-181
    • Essand, M.1    Asi, L.2
  • 81
    • 84858758766 scopus 로고    scopus 로고
    • Adoptive immunotherapy for cancer: Harnessing the T cell response
    • Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
    • (2012) Nat. Rev. Immunol , vol.12 , pp. 269-281
    • Restifo, N.P.1    Dudley, M.E.2    Rosenberg, S.A.3
  • 82
    • 79952187823 scopus 로고    scopus 로고
    • T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
    • Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620-626 (2011).
    • (2011) Mol. Ther , vol.19 , pp. 620-626
    • Parkhurst, M.R.1    Yang, J.C.2    Langan, R.C.3
  • 83
    • 65249101637 scopus 로고    scopus 로고
    • The promise and potential pitfalls of chimeric antigen receptors
    • Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215-223 (2009).
    • (2009) Curr. Opin. Immunol , vol.21 , pp. 215-223
    • Sadelain, M.1    Brentjens, R.2    Riviere, I.3
  • 84
    • 0024834988 scopus 로고
    • Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-Type specificity
    • Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-Type specificity. Proc. Natl Acad. Sci. USA 86, 10024-10028 (1989).
    • (1989) Proc. Natl Acad. Sci. USA , vol.86 , pp. 10024-10028
    • Gross, G.1    Waks, T.2    Eshhar, Z.3
  • 85
    • 33646440024 scopus 로고    scopus 로고
    • Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience
    • Lamers CHJ, Sleijfer S, Vulto AG et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22 (2006).
    • (2006) J. Clin. Oncol , vol.24
    • Chj, L.1    Sleijfer, S.2    Vulto, A.G.3
  • 86
    • 50549096284 scopus 로고    scopus 로고
    • Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    • Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271 (2008).
    • (2008) Blood , vol.112 , pp. 2261-2271
    • Till, B.G.1    Jensen, M.C.2    Wang, J.3
  • 87
    • 33947265424 scopus 로고    scopus 로고
    • Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
    • Park JR, DiGiusto DL, Slovak M et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825-833 (2007).
    • (2007) Mol. Ther , vol.15 , pp. 825-833
    • Park, J.R.1    Digiusto, D.L.2    Slovak, M.3
  • 88
    • 33750699642 scopus 로고    scopus 로고
    • A Phase i study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
    • Kershaw MH, Westwood JA, Parker LL et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115 (2006).
    • (2006) Clin. Cancer Res , vol.12 , pp. 6106-6115
    • Kershaw, M.H.1    Westwood, J.A.2    Parker, L.L.3
  • 89
    • 0347994955 scopus 로고    scopus 로고
    • Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRz chain
    • Finney HM, Akbar AN, Lawson ADG. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRz chain. J. Immunol. 172, 104-113 (2004).
    • (2004) J. Immunol , vol.172 , pp. 104-113
    • Finney, H.M.1    Akbar, A.N.2    Adg, L.3
  • 90
    • 33750061330 scopus 로고    scopus 로고
    • Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells
    • Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20, 1819-1828 (2006).
    • (2006) Leukemia , vol.20 , pp. 1819-1828
    • Loskog, A.1    Giandomenico, V.2    Rossig, C.3    Pule, M.4    Dotti, G.5    Brenner, M.K.6
  • 91
    • 79959914449 scopus 로고    scopus 로고
    • In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB
    • Song DG, Ye Q, Carpenito C et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71, 4617-4627 (2011).
    • (2011) Cancer Res , vol.71 , pp. 4617-4627
    • Song, D.G.1    Ye, Q.2    Carpenito, C.3
  • 92
    • 80051775476 scopus 로고    scopus 로고
    • T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
    • Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95) 95ra73 (2011).
    • (2011) Sci. Transl. Med , vol.3 , Issue.95
    • Kalos, M.1    Levine, B.L.2    Porter, D.L.3
  • 93
    • 80051720194 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    • Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
    • (2011) N. Engl. J. Med , vol.365 , pp. 725-733
    • Porter, D.L.1    Levine, B.L.2    Kalos, M.3    Bagg, A.4    June, C.H.5
  • 94
    • 84876325876 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    • Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
    • (2013) N. Engl. J. Med , vol.368 , pp. 1509-1518
    • Grupp, S.A.1    Kalos, M.2    Barrett, D.3
  • 96
    • 84866735170 scopus 로고    scopus 로고
    • Paths to stemness: Building the ultimate antitumour T cell
    • Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671-684 (2012).
    • (2012) Nat. Rev. Cancer , vol.12 , pp. 671-684
    • Gattinoni, L.1    Klebanoff, C.A.2    Restifo, N.P.3
  • 97
    • 79960975784 scopus 로고    scopus 로고
    • Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression
    • Li Q, Lao X, Pan Q et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 17, 4987-4995 (2011).
    • (2011) Clin. Cancer Res , vol.17 , pp. 4987-4995
    • Li, Q.1    Lao, X.2    Pan, Q.3
  • 98
    • 0015897005 scopus 로고
    • Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells
    • Oldham RK, Herberman RB. Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells. J. Immunol. 111, 862-871 (1973).
    • (1973) J. Immunol , vol.111 , pp. 862-871
    • Oldham, R.K.1    Herberman, R.B.2
  • 99
    • 0016746934 scopus 로고
    • Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells
    • Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16, 230-239 (1975).
    • (1975) Int. J. Cancer , vol.16 , pp. 230-239
    • Herberman, R.B.1    Nunn, M.E.2    Holden, H.T.3    Lavrin, D.H.4
  • 100
    • 0016762220 scopus 로고
    • Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype
    • Kiessling R, Klein E, Wigzell H. 'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112-117 (1975).
    • (1975) Eur. J. Immunol , vol.5 , pp. 112-117
    • Kiessling, R.1    Klein, E.2    Wigzell, H.3
  • 101
    • 69049110783 scopus 로고    scopus 로고
    • Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells
    • Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A. Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat. Immunol. 10, 973-980 (2009).
    • (2009) Nat. Immunol , vol.10 , pp. 973-980
    • Dong, Z.1    Cruz-Munoz, M.E.2    Zhong, M.C.3    Chen, R.4    Latour, S.5    Veillette, A.6
  • 102
    • 0037086131 scopus 로고    scopus 로고
    • Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    • Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002).
    • (2002) Science , vol.295 , pp. 2097-2100
    • Ruggeri, L.1    Capanni, M.2    Urbani, E.3
  • 103
    • 0032558759 scopus 로고    scopus 로고
    • Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
    • Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339, 1186-1193 (1998).
    • (1998) N. Engl. J. Med , vol.339 , pp. 1186-1193
    • Aversa, F.1    Tabilio, A.2    Velardi, A.3
  • 104
    • 20144388509 scopus 로고    scopus 로고
    • Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
    • Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005).
    • (2005) Blood , vol.105 , pp. 3051-3057
    • Miller, J.S.1    Soignier, Y.2    Panoskaltsis-Mortari, A.3
  • 105
    • 80053208226 scopus 로고    scopus 로고
    • Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
    • Curti A, Ruggeri L, D'Addio A et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118, 3273-3279 (2011).
    • (2011) Blood , vol.118 , pp. 3273-3279
    • Curti, A.1    Ruggeri, L.2    D'Addio, A.3
  • 106
    • 80053465574 scopus 로고    scopus 로고
    • Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression
    • Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17, 6287-6297 (2011).
    • (2011) Clin. Cancer Res , vol.17 , pp. 6287-6297
    • Parkhurst, M.R.1    Riley, J.P.2    Dudley, M.E.3    Rosenberg, S.A.4
  • 108
    • 32944468708 scopus 로고    scopus 로고
    • Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
    • Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12, 878-887 (2006).
    • (2006) Clin. Cancer Res , vol.12 , pp. 878-887
    • Antonia, S.J.1    Mirza, N.2    Fricke, I.3
  • 109
    • 33749005382 scopus 로고    scopus 로고
    • Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma
    • Inoges S, Rodriguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98, 1292-1301 (2006).
    • (2006) J. Natl Cancer Inst , vol.98 , pp. 1292-1301
    • Inoges, S.1    Rodriguez-Calvillo, M.2    Zabalegui, N.3
  • 110
    • 24944478531 scopus 로고    scopus 로고
    • Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
    • Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65, 8059-8064 (2005).
    • (2005) Cancer Res , vol.65 , pp. 8059-8064
    • Emens, L.A.1    Jaffee, E.M.2
  • 113
    • 83355163508 scopus 로고    scopus 로고
    • Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer
    • Shirota T, Kasuya H, Kodera Y et al. Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer. Hepatogastroenterology 58, 1482-1489 (2011).
    • (2011) Hepatogastroenterology , vol.58 , pp. 1482-1489
    • Shirota, T.1    Kasuya, H.2    Kodera, Y.3
  • 114
    • 79957902460 scopus 로고    scopus 로고
    • Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: Preclinical and clinical demonstration of combination efficacy
    • Heo J, Breitbach CJ, Moon A et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol. Ther. 19, 1170-1179 (2011).
    • (2011) Mol. Ther , vol.19 , pp. 1170-1179
    • Heo, J.1    Breitbach, C.J.2    Moon, A.3
  • 115
    • 84858702868 scopus 로고    scopus 로고
    • Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-Tumor immunity
    • Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-Tumor immunity. Cancer Gene Ther. 19, 238-246 (2012).
    • (2012) Cancer Gene Ther , vol.19 , pp. 238-246
    • Stephenson, K.B.1    Barra, N.G.2    Davies, E.3    Ashkar, A.A.4    Lichty, B.D.5
  • 116
    • 84869217555 scopus 로고    scopus 로고
    • Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
    • Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. General Virol. 93, 2529-2545 (2012).
    • (2012) J. General Virol , vol.93 , pp. 2529-2545
    • Hastie, E.1    Grdzelishvili, V.Z.2
  • 117
    • 84871025600 scopus 로고    scopus 로고
    • Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: Implication of leucocyte recruitment
    • Dempe S, Lavie M, Struyf S et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol. Immunother. 61, 2113-2123 (2012).
    • (2012) Cancer Immunol. Immunother , vol.61 , pp. 2113-2123
    • Dempe, S.1    Lavie, M.2    Struyf, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.